• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    9/29/25 4:27:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALV alert in real time by email
    8-K
    false 0001348911 0001348911 2025-09-24 2025-09-24
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 24, 2025

     

     

    KALVISTA PHARMACEUTICALS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-36830   20-0915291
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)
    200 Crossing Boulevard  
    Framingham, Massachusetts     01702
    (Address of Principal Executive Offices)     (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 857 999-0075

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.001 par value per share   KALV   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01. Entry into a Material Definitive Agreement.

    On September 29, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) completed its previously announced sale of $143.75 million in aggregate principal amount of its 3.250% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the Initial Purchasers’ (as defined below) option to purchase up to an additional $18.75 million in aggregate principal amount of Notes, to the Initial Purchasers in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and for initial resale by the Initial Purchasers to persons reasonably believed to be qualified institutional buyers pursuant to the exemption from registration provided by Rule 144A under the Securities Act.

    The Company estimates that the net proceeds from the offering are approximately $139.0 million, after deducting the Initial Purchasers’ discount and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes, including the commercialization of EKTERLY. The Company may also use a portion of the net proceeds from the offering for investments in and acquisitions of other companies, products or technologies in the future. However, the Company has no commitments or specific plans with respect to any such investments in and acquisitions of other companies, products or technologies at this time.

    The information set forth in Item 8.01 of this Current Report on Form 8-K under the heading “Indenture” is incorporated herein by reference.

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The terms and conditions of the Notes and Indenture described in Item 8.01 of this Current Report on Form 8-K are incorporated herein by reference.

    Item 3.02. Unregistered Sales of Equity Securities.

    The information set forth in Item 8.01 of this Current Report on Form 8-K under the headings “Purchase Agreement” and “Indenture” is incorporated herein by reference.

    Item 8.01. Other Events.

    Purchase Agreement

    On September 24, 2025, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several initial purchasers named in Schedule I thereto (the “Initial Purchasers”), relating to the Company’s sale of the Notes to the Initial Purchasers in a private placement in reliance on Section 4(a)(2) of the Securities Act and for initial resale by the Initial Purchasers to persons reasonably believed to be qualified institutional buyers pursuant to the exemption from registration provided by Rule 144A under the Securities Act. The Company relied on these exemptions from registration based in part on representations made by the Initial Purchasers. The Initial Purchasers exercised their option in full under the Purchase Agreement to purchase up to an additional $18.75 million aggregate principal amount of Notes in full on September 25, 2025. The Purchase Agreement includes customary representations, warranties and covenants by the Company. Under the terms of the Purchase Agreement, the Company agreed to indemnify the Initial Purchasers against certain liabilities under the Securities Act. The Notes and the shares of Common Stock issuable upon conversion of the Notes, if any, have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

    Indenture

    The Notes were issued pursuant to an Indenture, dated as of September 29, 2025 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee. The Notes are senior, unsecured obligations of the Company. The Notes will bear interest at a rate of 3.250% per year payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2026. The Notes mature on October 1, 2031,


    unless repurchased, redeemed or converted in accordance with their terms prior to such date. The Company may not redeem the Notes prior to October 5, 2028. The Company may redeem for cash all or part of the Notes, at its option, on or after October 5, 2028, and prior to July 1, 2031, if certain conditions are met. No sinking fund is provided for the Notes.

    The Indenture includes customary terms and covenants, including certain events of default after which the Notes may be due and payable immediately. The following events are considered “events of default,” which may result in acceleration of the maturity of the Notes:

     

      1.

    failure by the Company to pay the principal of the Notes when due and payable at its stated maturity, upon optional redemption, upon any required repurchase, upon declaration of acceleration or otherwise;

     

      2.

    failure by the Company to pay the interest on any Note when due and payable and such failure continues for a period of 30 days;

     

      3.

    failure by the Company to convert the Notes in accordance with the Indenture upon exercise of a holder’s conversion right and, in the case of a conversion to which physical settlement applies, such failure continues for three business days;

     

      4.

    failure by the Company to give a fundamental change repurchase right notice, a notice of specified corporate events or a notice of a make-whole fundamental change at the time and in the manner provided in the Indenture;

     

      5.

    failure by the Company to comply with its obligations under the Indenture with respect to a consolidation, merger or sale of assets of the Company;

     

      6.

    failure by the Company to perform any of the agreements contained in the Notes or the Indenture and such failure is not cured or waived within 60 days after notice is given to us by the trustee, or to the Company and the trustee by holders of at least 25% of the aggregate principal amount of Notes then outstanding, which notice must specify such default, demand that it be remedied and state that such notice is a “notice of default”;

     

      7.

    failure to pay at final maturity or upon acceleration any indebtedness for money borrowed by the Company or any of its significant subsidiaries (as defined in the Indenture) in an aggregate outstanding principal amount in excess of $25.0 million, which indebtedness is not discharged, or which acceleration is not cured or rescinded, within 30 days after written notice to the Company as provided in the Indenture;

     

      8.

    failure by the Company or any of its significant subsidiaries to pay one or more final and non-appealable judgments entered by a court or courts of competent jurisdiction, the aggregate uninsured or unbonded portion of which is in excess of $25.0 million, if the judgments are not paid, discharged or stayed within 30 days; or

     

      9.

    specified events of bankruptcy, insolvency or reorganization of the Company or any of its significant subsidiaries occurs.

    Upon conversion, the Company will satisfy its conversion obligation by paying or delivering, as the case may be, shares of Common Stock, cash or a combination of cash and shares of Common Stock, at the election of the Company. The initial conversion rate is 59.4919 shares of Common Stock per $1,000 principal amount of the Notes, which is equal to an initial conversion price of approximately $16.81 per share of Common Stock subject to adjustment. Initially, a maximum of 11,117,553 shares of Common Stock may be issued upon conversion of the Notes, based on the initial maximum conversion rate of 77.3395 shares of Common Stock per $1,000 principal amount of Notes. Prior to the close of business on the scheduled trading day immediately preceding July 1, 2031, such conversion is subject to the satisfaction of certain conditions set forth below.

    Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture) or convert their Notes called (or deemed called) for redemption in connection with any optional redemption are, under certain circumstances, entitled to an increase in the conversion rate. Additionally, in the event of a fundamental change (as defined in the Indenture), holders of the Notes may require the Company to repurchase for cash all or a portion of their Notes at a price equal to 100% of the principal amount of Notes, plus any accrued and unpaid interest to, but excluding, the repurchase date.


    Holders of the Notes may convert all or a portion of their Notes prior to the close of business on the business day immediately preceding July 1, 2031, in multiples of $1,000 principal amount, only under the following circumstances:

     

      •  

    during any calendar quarter commencing after the calendar quarter ending on December 31, 2025 (and only during such calendar quarter), if the last reported sale price of Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price of the Notes on each applicable trading day;

     

      •  

    during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of Common Stock and the conversion rate of the Notes on such trading day;

     

      •  

    if the Company calls any or all Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; or

     

      •  

    upon the occurrence of specified corporate events as specified in the Indenture.

    On or after July 1, 2031 until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding October 1, 2031, holders of the Notes may convert the Notes, in multiples of $1,000 principal amount, at their option regardless of the foregoing circumstances.

    A copy of the Indenture is attached hereto as Exhibit 4.1 and is incorporated herein by reference. The description of the Notes contained in this Form 8-K is qualified in its entirety by reference to the Indenture.

    Press Releases

    On September 24, 2025, the Company issued a press release announcing the proposed offering of the Notes. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    On September 24, 2025, the Company issued a press release announcing the pricing of the Notes. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.


    Cautionary Statement Regarding Forward-Looking Statements

    This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws. These statements include, but are not limited to, the expected use of net proceeds from the offering of the Notes. Forward-looking statements include all statements that are not historical facts. In some cases, forward-looking statements can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “will,” or similar expressions and the negatives of those words. Forward-looking statements involve substantial risks and uncertainties that may cause actual results to differ materially from those that the Company expects. These risks and uncertainties include market risks, trends, and conditions. For information about other potential factors that could affect the Company’s business and financial results, please review the “Risk Factors” described in KalVista Pharmaceutical’s Annual Report on Form 10-K for the year ended April 30, 2025 filed with the Securities and Exchange Commission (the “SEC”) on July 10, 2025 and in the Company’s other filings with the SEC. Except as may be required by law, the Company does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    Number

      

    Description

     4.1    Indenture dated September 29, 2025 between KalVista Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee (including the form of 3.250% Convertible Senior Notes due 2031).
    99.1    Press release dated September 24, 2025 announcing the proposed offering of the Notes.
    99.2    Press release dated September 24, 2025 announcing the pricing of the offering of the Notes.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          KALVISTA PHARMACEUTICALS, INC.
    Date: September 29, 2025     By:  

    /s/ Brian Piekos

          Brian Piekos
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    Get the next $KALV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KALV

    DatePrice TargetRatingAnalyst
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    1/7/2025$30.00Buy
    TD Cowen
    12/18/2024$22.00Buy
    BofA Securities
    3/11/2022$48.00 → $42.00Buy
    Needham
    12/10/2021$50.00 → $48.00Buy
    Needham
    More analyst ratings

    $KALV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on KalVista Pharmaceuticals with a new price target

    JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

    1/31/25 7:03:28 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on KalVista Pharmaceuticals with a new price target

    TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00

    1/7/25 7:55:33 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on KalVista Pharmaceuticals with a new price target

    BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00

    12/18/24 7:36:39 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    4/11/25 5:22:07 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/14/25 7:45:15 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/11/25 7:51:08 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 15,625 shares and sold $115,537 worth of shares (7,294 units at $15.84), increasing direct ownership by 2% to 395,189 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    9/9/25 7:02:04 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Sweeny Nicole converted options into 5,000 shares and sold $19,862 worth of shares (1,480 units at $13.42), increasing direct ownership by 12% to 32,291 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    8/26/25 8:00:34 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,125 shares and sold $26,223 worth of shares (1,954 units at $13.42), increasing direct ownership by 0.89% to 132,052 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    8/26/25 7:59:05 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

    KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20th German Allergy Congress taking place in Düsseldorf, Germany from October 2–4, 2025. Details are as follows: Thursday, October 2 at 4:00–5:15 pm CEST: Time to End of Progression of Hereditary Angioedema Attacks Treated with Sebetralstat: Markus Magerl, Inmaculada Martinez-Saguer, William R. Lumry, John Anderson, Jonathan A. Bernstein, Mauro Cancian, Danny M. Cohn, Henriette Farkas, Henry Li, James Hao, Michael Smith, Paolo Bajcic, Paul Audhya, Petra Staubach, Emel Aygören-Pürsün. Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks in E

    9/26/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

    KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV), announced today the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the offering was increased from the previously announced offering size of $110.0 million. KalVista also granted the initial purchasers of the notes an option to purchase, for settlement within a 13-day period from, and including, the date on which the notes are first issued, u

    9/24/25 10:52:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

    KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). KalVista also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period from, and including, the date on which the notes are first issued, up to an additional $15.0 million aggregate principal amount of notes. The note

    9/24/25 4:01:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Leadership Updates

    Live Leadership Updates

    View All

    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable

    8/11/25 4:05:00 PM ET
    $KALV
    $MGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    KalVista Appoints Jeb Ledell as Chief Operating Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. "I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity," said Ben Palleiko, Chief Executive Officer of KalVista. "I am confident that his proven skills will help us to achieve our goal of delivering s

    12/16/24 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. "I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors," said Ben Palleiko, Chief Executive Officer of KalVista. "His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization." "I am excited to join the KalVist

    11/26/24 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Financials

    Live finance-specific insights

    View All

    KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

    -EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through August- -European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October- -$191M in cash, providing runway into 2027- -Management to host conference call today at 8:30 a.m. ET- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. "This quarter marked a defining mome

    9/11/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

    First new on-demand HAE treatment in over a decade, with potential to transform management of the disease Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or use of long-term prophylaxis, and well-established safety profile Management to host conference call today at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand t

    7/7/25 6:30:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

    – Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l

    2/13/24 6:30:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 3:57:49 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

    SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 12:02:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KALV
    SEC Filings

    View All

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    9/29/25 4:27:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by KalVista Pharmaceuticals Inc.

    10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    9/11/25 7:45:42 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    9/11/25 7:24:23 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care